Valtoco (diazepam) is a prescription drug that’s used to treat seizure clusters in adults and certain children. Valtoco comes as a nasal spray. Valtoco contains the active ingredient diazepam. It ...

Valtoco (diazepam nasal spray) is a prescription medicine for quick and effective treatment of seizure clusters, also known as acute repetitive seizures, in people with epilepsy. Seizure clusters are ...

Presentation highlights study-enrollment challenges and strategies to overcome potential barriers "Data from clinical studies of repetitive seizures in early childhood are critical to help advance new ...

In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years. The Food and Drug ...

SAN DIEGO, April 16, 2025 /PRNewswire/ -- Neurelis, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of ...

The first Food and Drug Administration-approved diazepam nasal spray now is available. Neurelis' Valtoco, which was approved in January, has officially launched. “We understand the high unmet need for ...

Fifth patent combined with a growing body of clinical data demonstrate safety and effectiveness of VALTOCO in this patient population, enhancing potential to expand clinical and commercial value. SAN ...

SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today provides a business update highlighting the Company's recent achievements in ...

Neurelis announced the availability of Valtoco® (diazepam nasal spray) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute ...

VALTOCO maintains orphan drug exclusivity for VALTOCO to treat episodes of frequent seizures SAN DIEGO, April 16, 2025 /PRNewswire/ -- Neurelis, Inc., today announced that the U.S. Food and Drug ...